SMR3A: A Potential Drug Target for Cancer (G26952)

Target Name: SMR3A

NCBI ID: G26952

SMR3A

SMR3A: A Potential Drug Target for Cancer

SMR3A, also known as PROL5, is a gene that has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 16 and encodes a protein known as SMR3A protein.

SMR3A has been shown to play a role in a variety of cellular processes, including cell division, apoptosis (programmed cell death), and tissue repair. It is also involved in the development and maintenance of tissues, such as blood vessels and heart tissue.

Research has also shown that SMR3A is often expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It is also expressed in precancerous cells, which can develop into cancer if left untreated.

One of the key reasons why SMR3A has been identified as a potential drug target is its involvement in the regulation of cell growth and apoptosis. Studies have shown that SMR3A plays a role in the regulation of cell cycle progression, and that it is involved in the formation of mitochondrial organelles, which are important for cell energy metabolism.

Additionally, SMR3A has also been shown to be involved in the regulation of cell apoptosis, which is the process by which cells die naturally in response to external stress, such as exposure to toxins or radiation. Studies have shown that SMR3A plays a role in the regulation of cell apoptosis and that it is involved in the formation of apoptotic cells.

Another potential mechanism by which SMR3A may be involved in the development of cancer is its role in tissue repair and regeneration. Studies have shown that SMR3A is involved in the regulation of cell proliferation and cell differentiation, which are important processes for tissue repair and regeneration.

SMR3A has also been shown to be involved in the regulation of immune response, which is important for the fight against cancer. Studies have shown that SMR3A is involved in the regulation of T cell development and that it is involved in the regulation of immune cell proliferation.

In addition to its potential role in the regulation of cell growth, apoptosis, and tissue repair, SMR3A has also been shown to be involved in the development and maintenance of various diseases, including cancer. Studies have shown that SMR3A is often expressed in various types of cancer and that it is involved in the development and progression of these diseases.

SMR3A has also been shown to be involved in the regulation of pain perception, which is an important aspect of cancer treatment. Studies have shown that SMR3A is involved in the regulation of pain perception and that it is involved in the development of pain tolerance.

Overall, SMR3A is a gene that has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer. Further research is needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: Submaxillary Gland Androgen Regulated Protein 3A

Functions: May play a role in protection or detoxification

The "SMR3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMR3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets